{"id":"peg-ifn-2b-combined-with-nas","safety":{"commonSideEffects":[{"rate":"40-70","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"10-30","effect":"Hematologic toxicity (neutropenia, thrombocytopenia)"},{"rate":"5-15","effect":"Psychiatric effects (depression, anxiety)"},{"rate":"5-10","effect":"Thyroid dysfunction"},{"rate":"10-20","effect":"Injection site reactions"},{"rate":"20-40","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL405705","moleculeType":"Small molecule","molecularWeight":"1256.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Peg-IFN α-2b is a long-acting interferon that activates innate and adaptive immune responses to clear HBV-infected hepatocytes. Nucleos(t)ide analogues (NAs) such as lamivudine, entecavir, or tenofovir directly inhibit HBV reverse transcriptase, suppressing viral replication. The combination approach leverages both immune activation and direct antiviral activity to achieve sustained virological response and HBeAg/HBsAg clearance.","oneSentence":"Pegylated interferon alpha-2b combined with nucleos(t)ide analogues works by enhancing immune response against hepatitis B virus while simultaneously inhibiting viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:41:48.399Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection (HBeAg-positive or HBeAg-negative)"},{"name":"HBV with compensated liver disease"}]},"trialDetails":[{"nctId":"NCT07069569","phase":"PHASE2","title":"A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2025-05-30","conditions":"Chronic Hepatitis B","enrollment":127},{"nctId":"NCT07079150","phase":"","title":"Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study","status":"RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2025-01-01","conditions":"Hepatitis B, Chronic (CHB), Hepatitis B, Hepatitis B Virus (HBV)","enrollment":1500},{"nctId":"NCT07071636","phase":"PHASE4","title":"Clinical Efficacy of Pegylated Interferon Alpha-2b Combined With Nucleos(t)Ide Analogues in the Treatment of Chronic Hepatitis B Patients","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-08-15","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease, Chronic Hepatitis B","enrollment":830},{"nctId":"NCT05922306","phase":"EARLY_PHASE1","title":"Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B","status":"RECRUITING","sponsor":"Anhui Medical University","startDate":"2023-07","conditions":"Hepatitis B, Chronic","enrollment":1084},{"nctId":"NCT01935635","phase":"PHASE1, PHASE2","title":"A Clinical Trial on HB-Vac Activated-DCs Combined With Peg-IFN or NAs in CHB","status":"COMPLETED","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-01","conditions":"Chronic Hepatitis B","enrollment":400},{"nctId":"NCT03969017","phase":"PHASE2","title":"Combination Treatment of NAs and Peg IFN α-2b for Hepatitis B Related, Compensatory Cirrhosis Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-06-17","conditions":"Cirrhosis of Liver Due to Hepatitis B (Disorder)","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Peg-IFN α-2b combined with NAs","genericName":"Peg-IFN α-2b combined with NAs","companyName":"Shenzhen Third People's Hospital","companyId":"shenzhen-third-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated interferon alpha-2b combined with nucleos(t)ide analogues works by enhancing immune response against hepatitis B virus while simultaneously inhibiting viral replication. Used for Chronic hepatitis B infection (HBeAg-positive or HBeAg-negative), HBV with compensated liver disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}